for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang CONBA Pharmaceutical Co., Ltd.

600572.SS

Latest Trade

6.77CNY

Change

0.08(+1.20%)

Volume

53,938,915

Today's Range

6.65

 - 

6.89

52 Week Range

5.62

 - 

11.28

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
6.69
Open
6.71
Volume
53,938,915
3M AVG Volume
835.53
Today's High
6.89
Today's Low
6.65
52 Week High
11.28
52 Week Low
5.62
Shares Out (MIL)
2,570.04
Market Cap (MIL)
18,057.76
Forward P/E
--
Dividend (Yield %)
2.22

Next Event

Q3 2019 Zhejiang CONBA Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Zhejiang CONBA Pharmaceutical's H1 Net Profit Down, To Buy Chinese Medicines Firm

Zhejiang CONBA To Issue Medium-Term Notes And Commercial Paper, To Transfer Stake In Biopharma

Zhejiang Conba Pharmaceutical's 9-Month Net Profit Up 26.27 Pct Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zhejiang CONBA Pharmaceutical Co., Ltd.

Zhejiang CONBA Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.

Industry

Major Drugs

Contact Info

Binjiang Technological & Economc Prk

No.568 Bnkng Rd,

Hi-Tech Development Zone

+86.571.87774710

http://gfgs.conbagroup.com/

Executive Leadership

Jiqiang Hu

Chairman of the Board

Ruwei Wang

President, Director

Wei Liang Zhang

Vice Chairman of the Board

Zhenxian Yuan

Chief Financial Officer

Yuezhong Chen

Finance Director, Vice President

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
EPS (CNY)

2016

0.180

2018

0.301
Price To Earnings (TTM)
28.00
Price To Sales (TTM)
2.63
Price To Book (MRQ)
3.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
64.74
LT Debt To Equity (MRQ)
23.21
Return on Investment (TTM)
9.96
Return on Equity (TTM)
6.33

Latest News

Latest News

BRIEF-Shanghai Exchange Filing Shows Block Trade Of Zhejiang Conba Pharmal Involving 372.36 Mln Yuan

* FILING SHOWS BLOCK TRADE OF ZHEJIANG CONBA PHARMACEUTICAL CO LTD'S 53.35 MILLION SHARES INVOLVING 372.36 MILLION YUAN ($58.56 million) ON MAY 2 Source text in Chinese: https://bit.ly/2yJZikT Further company coverage: ($1 = 6.3587 Chinese yuan renminbi) (Reporting by Hong...

BRIEF-Zhejiang CONBA Pharmaceutical to pay annual cash div as 1.50 yuan per 10 shares for FY 2017

* Says it plans to pay annual cash dividend as 1.50 yuan(pre-tax) per 10 shares as FY 2017 div payment

BRIEF-Zhejiang Conba Pharmaceutical's 2017, Q1 Profit Up

* SAYS 2017 NET PROFIT UP 61.2 PERCENT Y/Y AT 711.1 MILLION YUAN ($112.45 million)

BRIEF-Zhejiang Conba Pharmaceutical's Share Trade To Resume On April 18

* SAYS SHARE TRADE TO RESUME ON APRIL 18 Source text in Chinese: https://bit.ly/2HIphKM Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Conba Pharmaceutical's Consortium Acquires Stake In Jiangxi Chinese Medicine Firm

* SAYS ITS CONSORTIUM ACQUIRES 41 PERCENT STAKE IN JIANGXI CHINESE MEDICINE FIRM FOR 300.35 MILLION YUAN ($47.84 million) Source text in Chinese: https://bit.ly/2v9X0Kh Further company coverage: ($1 = 6.2785 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Conba Pharmaceutical Says Lock-Up Period For 446.25 Million Shares To End

* SAYS LOCK-UP PERIOD FOR 446.25 MILLION SHARES TO END, SHARES TO START TRADING ON APRIL 16 Source text in Chinese: https://bit.ly/2EA5Yjp Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang CONBA Pharmaceutical to set up traditional Chinese medicinal materials unit in Zhejiang

* Says it plans to invest 100 million yuan to set up a wholly owned traditional Chinese medicinal materials unit in Zhejiang

BRIEF-Zhejiang Conba Pharmaceutical issues 156.6 mln shares and raises 1.09 bln yuan

* Says it issued 156.6 million shares and raised 1.09 billion yuan in total, via private placement

BRIEF-Zhejiang Conba Pharmaceutical Sees 2017 Net Profit Up 60-80 Percent Y/Y

* SAYS IT EXPECTS 2017 NET PROFIT TO RISE 60-80 PERCENT Y/Y FROM 441.1 MILLION YUAN ($67.65 million) YEAR AGO Source text in Chinese: http://bit.ly/2CRWSBQ Further company coverage: ($1 = 6.5205 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Conba Pharmaceutical two units obtains high-tech enterprise recognition

* Says its two wholly owned Guizhou and Inner Mongolia-based pharma units obtains high-tech enterprise recognition, to enjoy a tax preference of 15 percent for three years from 2017 to 2019

BRIEF-Zhejiang CONBA Pharmaceutical's 9-month net profit up 34.9 pct y/y

* Says 9-month net profit up 34.9 percent y/y at 607.1 million yuan ($91.74 million)

BRIEF-Zhejiang Conba Pharmaceutical gets approval to issue 1.5 bln yuan medium-term notes

* Says it gets approval to issue 1.5 billion yuan ($228.81 million) medium-term notes

BRIEF-Zhejiang Conba Pharmaceutical's H1 net profit up 25.2 pct y/y

* Says H1 net profit up 25.2 percent y/y at 384.6 million yuan ($57.66 million)

BRIEF-Zhejiang CONBA Pharmaceutical unit received approval for drug clinical trials

* Says its controlling unit has been granted approval for drug clinical trials for pirfenidone tablets issued by china food and drug administration

BRIEF-Zhejiang CONBA Pharma's prelim H1 profit up 25.3 pct y/y

* Says preliminary H1 net profit up 25.3 percent y/y at 384.9 million yuan ($56.61 million)

BRIEF-Zhejiang Conba Pharmaceutical's controlling shareholder to add up to 2 pct stake in next 6 months

* Says its controlling shareholder plans to add up to 2 percent stake in next 6 months

BRIEF-Zhejiang CONBA Pharmaceutical says dividend payment date

* Says it will pay a cash dividend of 0.12 yuan per share(before tax) for 2016 to shareholders of record on June 15

BRIEF-Zhejiang Conba Pharma's board elects chairman

Zhejiang Conba Pharmaceutical Co Ltd * Says board elects Hu Jiqiang as chairman Source text in Chinese: http://bit.ly/2pjt4b6 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Conba Pharmaceutical to pay cash div 1.20 yuan per 10 shares for FY 2016

* Says it plans to pay cash div 1.20 yuan per 10 shares for FY 2016

BRIEF-Zhejiang CONBA Pharmaceutical's 2016 net profit up 0.2 pct y/y

* Says 2016 net profit up 0.2 percent y/y at 441.1 million yuan ($64.07 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up